Literature DB >> 24942020

Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought?

Camden Hebson1, Tamara New, Elizabeth Record, Matthew Oster, Alexandra Ehrlich, William Border, Angelica James-Herry, Usama Kanaan.   

Abstract

Although elevated tricuspid regurgitant velocity (TRV), an echocardiographic marker for pulmonary hypertension, has previously been tied to mortality in adult patients with sickle cell disease, recent data demonstrated that it correlates poorly with catheterization findings. We describe the largest echocardiographic evaluation of pediatric patients with sickle cell disease to date, specifically the results of a protocol whereby a TRV≥250 cm/s prompted further evaluation. We investigated if elevated TRV would independently identify patients at risk for increased morbidity. A clinical echocardiographic database containing 630 patients with sickle cell disease was retrospectively reviewed; 120 patients (19%) met inclusion criteria and were compared 1:1 to randomly selected age-matched controls from the same database. By multivariate analysis, the elevated TRV cohort did not differ from controls in likelihood of acute chest episodes, hospitalization, or stroke. The study cohort's mean TRV in fact decreased to 242±33 cm/s at follow-up without a discernible and comprehensive intervention to explain the improvement. Three patients had catheterization-proven pulmonary hypertension. In conclusion, elevated TRV in children with sickle cell disease is less prevalent than previously thought and is not independently associated with increased short-term morbidity.

Entities:  

Mesh:

Year:  2015        PMID: 24942020     DOI: 10.1097/MPH.0000000000000184

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

Review 1.  Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication.

Authors:  Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-23

2.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

Review 3.  What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?

Authors:  Shaina M Willen; Mark T Gladwin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups - revisiting this controversial concept after 16 years of additional evidence.

Authors:  Payal Shah; Silvie Suriany; Roberta Kato; Adam M Bush; Patjanaporn Chalacheva; Saranya Veluswamy; Christopher C Denton; Kelly Russell; Maha Khaleel; Henry J Forman; Michael C K Khoo; Richard Sposto; Thomas D Coates; John C Wood; Jon Detterich
Journal:  Am J Hematol       Date:  2020-10-12       Impact factor: 10.047

5.  Pulmonary hypertension and right ventricular function in Nigerian children with sickle cell anaemia.

Authors:  Igoche D Peter; Mustafa O Asani; Shehu U Abdullahi; Ibrahim Aliyu; Stephen K Obaro; Fidelia Bode-Thomas
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-08-01       Impact factor: 2.184

Review 6.  Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.

Authors:  Katherine C Wood; Mark T Gladwin; Adam C Straub
Journal:  Heart       Date:  2019-12-10       Impact factor: 5.994

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.